Median Technologies · EURONEXT:ALMDT
Median Technologies — Actifin Paris (October 2020)
25 slides from Median Technologies's conference presentation, Oct 28, 2020
Slide 1: Median Technologies: The Imaging Phenomics Company
Median Technologies The Imaging Phenomics Company® Fredrik Brag, CEO Fredrik.brag@mediantechnologies.com
Slide 2: Median's Executive Team
Median’s Executive Team Fredrik Brag Bernard Reymann Yan Liu Nozha Boujemaa Nicolas Dano Robin Zhang Sophie Campagno CEO Chief Financial Officer Chief Medical Officer Chief Science and Chief Operating Officer General Manager Chief of Administration, & Co-founder Innovation Officer iCRO of China, iCR
Slide 3: Company's Shareholding Structure
Company’s Shareholding Structure Publicly held, listed on Euronext Growth Paris, ISIN: FR0011049824, Ticker: ALMDT Our People: As of September 2020, 140+ employees worldwide (EU, US and China), Shareholding structure as of June 19, 2020 30% working in Research and Development 3 www.mediantechnologie
Slide 4: Q3 2020 Financial Performance (unaudited figures)
Q3 2020 Financial Performance (unaudited figures) Revenue Order backlog • Q3 2020 revenue up 50% to €3.5 million, • Order backlog to €50.7 million as of September compared with €2.3 million in Q3 2019 30th, 2020, • 8 consecutive quarters of revenue growth • Revenues totalling €9.4m over the first th
Slide 5: iBiopsy
iBiopsy® We are developing imaging tests to help: • drug companies get new therapies to market faster • advanced cancer patients get the right treatment • monitor recurrence in cancer survivors. • detect early cancer in high-risk populations 5 www.mediantechnologies.com | October 28, 2020
Slide 6: iBiopsy Platform: Image Sequencing, Integrated AI
iBiopsy®Platform: Image Sequencing, Integrated AI The iBiopsy® platform leverages Median’s expertise and capabilities in: – Imaging technology – AI and data science – Clinical development – Regulatory and reimbursement • Partnership with Assistance Publique-Hôpitaux de Paris (AP-HP) one of the Europ
Slide 7: How big is the market opportunity, market segments
How big is the market opportunity, market segments U.S. ANNUAL TOTAL ADDRESSABLE MARKET (TAM): $30-$130B Early Cancer High Risk Treatment Cancer Recurrence Biopharma Detection/Screening Detection/Screening Selection Monitoring and MDR Development ~$5-50B ~$2-5B depending on the ~$2.5B ~$20-75B >$1B
Slide 8: iBiopsy Platform: Image Sequencing, Integrated AI
iBiopsy®Platform: Image Sequencing, Integrated AI Look Beyond What You See™️: Lesion-agnostic paradigm • Comprehensive digital image signatures extraction Whole-Organ Analysis using proprietary whole-organ analysis applied to multiple organs to describe and identify new generations of non-invasive b
Slide 9: iBiopsy Is a Paradigm Shift in Medical Image Analysis
iBiopsy® Is a Paradigm Shift in Medical Image Analysis Novel Multimodal AI Analysis for Finer Patient Stratification ML & AI Advanced Techno Analytics Cloud Solutions Extraction Prediction Classification Matching patients with best treatments in predictive and precision medicine Imaging Signatures L
Slide 10: iBiopsy: The Drive for Noninvasive Biomarkers
iBiopsy ® : The Drive for Noninvasive Biomarkers Biopsy Liquid Biopsy iBiopsy® Non-invasive procedure No No Yes Patient risk High Low Low Standardized and cost-effective procedure No No Yes Standard of care for every stage of cancer, No No Yes screening, diagnosis, and monitoring Detection of DNA mu
Slide 11: Initial Clinical Development Plans
Initial Clinical Development Plans The Pheno IDX Portfolio CDP Biomarker Indication Market First result application announcements Drug Development Patient Care (small cohorts) NASH Screening NAFLD Patient recruitment Early detection of Late 2020 – Diagnosis biomarker for clinical trial advanced form
Slide 12: First Results: HCC Recurrence Prediction in Resected Patients
First Results: HCC Recurrence Prediction in Resected Patients Performance Comparison for Significant Fibrosis (F ≥ 3) – Cohort: 94 patients Non-invasive Biopsy Liquid Biopsy Imaging Transient Multiparametric iBiopsy® iBiopsy® Metavir Score Fib-4 FibroTest Elastography Elastography MRI (training) (va
Slide 13: First Results: iBiopsy Extracts CD8+ Signature
First Results: iBiopsy® Extracts CD8+ Signature and Better Predicts Immune Microenvironment than Traditional Radiomics Traditional Radiomics1 iBiopsy® Image pre- Automated organ segmentation/no tumor Tumor manual segmentation processing segmentation Region of interest Tumor and peripheral ring Whole
Slide 14: Payer coverage and reimbursement
Payer coverage and reimbursement We can help payers reduce diagnostic and treatment costs while improving clinical outcome We believe our products offer significant health economic values in the following ways: • Reduce the need for a repeat invasive biopsy. Biopsies are not representative of the wh
Slide 15: Some Precision Medicine Comparables
Some Precision Medicine Comparables Data-driven patient profiling – Liquid Image Intent of use Biomarker Biopsy Machine learning + Data Library + biopsy biopsy CBIR CANCER - Therapy selection, early detection and recurrence Blood NO YES NO No AI, No search engine monitoring CANCER - Early detection
Slide 16: Our Strategy
Our Strategy Clinical development Business, partnerships and regulatory pathway • We will invest in our own clinical studies and • Leverage our iBiopsy® platform to expand our product develop strategic relationship with portfolio biopharmaceutical companies and luminary health institutions worldwide
Slide 17: iBiopsy Value Drivers: a Four-pillar Approach
iBiopsy® Value Drivers: a Four-pillar Approach CLINICAL VALIDATION REGULATORY • Established strategic partnerships with KOLs • At least 2 FDA approved products (Pheno IDX) and major clinical centers for data access and • Reimbursement codes in place with strong clinical expertise revenue ramp up tre
Slide 18: iCRO Business
iCRO Business Solutions and Services for Image Management in Clinical Trials 18 www.mediantechnologies.com | October 28, 2020
Slide 19: Imaging CRO Solutions and Services
Imaging CRO Solutions and Services Bringing more meaning to image data: iSee® • Image analysis and data management • Limits variability and increases reproducibility platform by automatically identifying, quantifying, and tracking lesions across all time points • Extracts more data from an image tha
Slide 20: Imaging CRO Solutions and Services
Imaging CRO Solutions and Services Bringing more meaning to image data: iSee® 20 www.mediantechnologies.com | October 28, 2020
Slide 21: Experience by Phase
Experience by Phase 122 studies (As of August 20, 2020) 28 Phase I trials Including 13 trials with Immunotherapy 122 studies also means: • 40+ clients in the US and Europe, 4 Phase I/II trials Top 10 including 1 Top 3 [1] 15 Including 9 trials with Immunotherapy • 10+ clients in China, including the
Slide 22: iCRO opportunities
iCRO opportunities Landscape • The global contract research organization (CRO) services market size was valued at USD 38bn in 2018 and is projected to reach USD 91bn by 2026 [1] • The largest market is in oncology • Competitive imaging CRO landscape: fragmented competition with 3 major players: Bioc
Slide 23: Take Away Messages
Take Away Messages 23 www.mediantechnologies.com | October 28, 2020
Slide 24: 2020 and Beyond
2020 and Beyond iBiopsy® • Very strong push for precision medicine and non-invasive biomarkers from patients, regulatory agencies (FDA, EMA…) and payers • Initial promising results for HCC recurrence risk prediction and biomarkers for IO responders/non responders CDPs • Clinical and technology partn
Slide 25: Our Core Values
Our Core Values Leading innovation with purpose Combine the spirit of innovation with our passion and conviction to help cure cancer and other debilitating diseases. Committing to quality in all we do Be dedicated to quality in everything we do. Quality begins with us and we are committed to it. Sup